AR099283A1 - Composiciones y métodos para el tratamiento de enfermedades virales con moduladores de la pde4 - Google Patents

Composiciones y métodos para el tratamiento de enfermedades virales con moduladores de la pde4

Info

Publication number
AR099283A1
AR099283A1 ARP140104158A ARP140104158A AR099283A1 AR 099283 A1 AR099283 A1 AR 099283A1 AR P140104158 A ARP140104158 A AR P140104158A AR P140104158 A ARP140104158 A AR P140104158A AR 099283 A1 AR099283 A1 AR 099283A1
Authority
AR
Argentina
Prior art keywords
treatment
compositions
methods
viral diseases
pde4 modulators
Prior art date
Application number
ARP140104158A
Other languages
English (en)
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of AR099283A1 publication Critical patent/AR099283A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/46—Iso-indoles; Hydrogenated iso-indoles with an oxygen atom in position 1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Reivindicación 1: Un método para el tratamiento o prevención de una condición o enfermedad inducida por un virus, que comprende la administración, a un paciente en necesidad de este, de una cantidad efectiva de 3-(3,4-dimetoxifenil)-3-(1-oxoindolin-2-il)propionamida (Compuesto A) o una sal, solvato o hidrato farmacéuticamente aceptables de este. Reivindicación 15: Un método para el tratamiento o prevención de una condición o enfermedad inducida por un virus, que comprende la administración, a un paciente en necesidad de este, de una cantidad efectiva de N-(2-(1-(3-etoxi-4-metoxifenil)-2-(metilsulfonil)etil)-3-oxoisoindolin-4-il)ciclopropancarboxamida (Compuesto B) o una sal, solvato o hidrato farmacéuticamente aceptables de este.
ARP140104158A 2013-11-06 2014-11-05 Composiciones y métodos para el tratamiento de enfermedades virales con moduladores de la pde4 AR099283A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361900489P 2013-11-06 2013-11-06

Publications (1)

Publication Number Publication Date
AR099283A1 true AR099283A1 (es) 2016-07-13

Family

ID=51999519

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP140104158A AR099283A1 (es) 2013-11-06 2014-11-05 Composiciones y métodos para el tratamiento de enfermedades virales con moduladores de la pde4

Country Status (14)

Country Link
US (1) US20160289188A1 (es)
EP (1) EP3065778A1 (es)
JP (1) JP2016540041A (es)
KR (1) KR20160068981A (es)
CN (1) CN105873611A (es)
AR (1) AR099283A1 (es)
AU (1) AU2014346877A1 (es)
CA (1) CA2929539A1 (es)
EA (1) EA201690937A1 (es)
IL (1) IL245511A0 (es)
MX (1) MX2016005808A (es)
PH (1) PH12016500824A1 (es)
SG (1) SG11201603469UA (es)
WO (1) WO2015069711A1 (es)

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5605914A (en) * 1993-07-02 1997-02-25 Celgene Corporation Imides
MXPA05005161A (es) * 2002-11-18 2005-07-22 Celgene Corp Metodos de utilizacion y composiciones que comprenden (-)3- (3, 4-dimetoxi- fenil)-3 -(1-oxo -1, 3-dihidro- isoindol- 2-il)- propionamida.
CN1452982A (zh) * 2003-06-25 2003-11-05 上海兴康医药研究开发有限公司 用于预防sars的利巴韦林黏膜给药制剂及制备方法
CN1972684A (zh) * 2004-04-23 2007-05-30 细胞基因公司 用于治疗和控制肺高血压的含有pde4调节剂的组合物以及其使用方法
WO2007139150A1 (ja) * 2006-05-30 2007-12-06 The University Of Tokushima ＴＮＦα阻害物質を含有してなる抗インフルエンザウイルス剤
MX2010002278A (es) * 2007-08-27 2010-03-17 Siga Technologies Inc Farmacos antivirales para el tratamiento de una infeccion por arenavirus.
US20100080807A1 (en) * 2008-09-26 2010-04-01 National Taiwan University Methods and Compositions for Treating Viral Hemorrhagic Fever
US20100297033A1 (en) * 2009-05-21 2010-11-25 Mcleay Matthew T Megaribavirin alone or combination of other antiviral, antioxidant and a perflubron emulsion for treatment of viral disease
US9408831B2 (en) * 2010-04-07 2016-08-09 Celgene Corporation Methods for treating respiratory viral infection
WO2012118599A1 (en) * 2011-02-28 2012-09-07 Emory University C-abl tyrosine kinase inhibitors useful for inhibiting filovirus replication

Also Published As

Publication number Publication date
JP2016540041A (ja) 2016-12-22
US20160289188A1 (en) 2016-10-06
SG11201603469UA (en) 2016-05-30
IL245511A0 (en) 2016-06-30
WO2015069711A1 (en) 2015-05-14
CA2929539A1 (en) 2015-05-14
KR20160068981A (ko) 2016-06-15
AU2014346877A1 (en) 2016-05-26
MX2016005808A (es) 2016-07-18
EP3065778A1 (en) 2016-09-14
EA201690937A1 (ru) 2017-02-28
CN105873611A (zh) 2016-08-17
PH12016500824A1 (en) 2016-06-13

Similar Documents

Publication Publication Date Title
CL2019001433A1 (es) Moduladores de la proteína core de la hepatitis b. (divisional solicitud 201800684)
CO2019015090A2 (es) Métodos de tratamiento para la fibrosis cística
CR20200064A (es) Carboxamidas como moduladores de los canales de sodio
CY1120049T1 (el) (2s)-ν-[(1s)-1-κυανο-2-φαινυλαιθυλ]-1,4-οξαζεπαν-2-καρβοξαμιδια ως αναστολεις της διπεπτιδυλικης πεπτιδασης i
AR109452A1 (es) Formulación farmacéutica de un inhibidor de lsd1 y método de tratamiento
BR112019003504A2 (pt) compostos de amino-pirrolopirimidinona e métodos de uso dos mesmos
WO2015103438A3 (en) Oncolytic virus adjunct therapy with agents that increase virus infectivity
CL2016001874A1 (es) Forma de dosificación oral sólida de liberación modificada que comprende pridopidina y un excipiente de control de velocidad; formulación farmacéutica que comprende a la forma de dosificación; uso de la forma de dosificación o de la formulación farmacéutica para tratar una enfermedad neurodegenerativa o relacionada con dopamina, como la enfermedad de huntington, entre otras.
GT201500020A (es) Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b
EA201692436A1 (ru) Медицинское применение
EA201892657A1 (ru) Спиролактамовые модуляторы nmda-рецептора и их применение
CR20180253A (es) Composiciones terapéuticas para el tratamiento del virus de unmunodeficiencia humana
UY35624A (es) Uso de dosis elevadas de pridopidina para tratar la enfermedad de huntington
MY201105A (en) Nucleotide hemi-sulfate salt for the treatment of hepatitis c virus
EA201990425A1 (ru) Спиролактамовые и бис-спиролактамовые модуляторы nmda-рецептора и их применение
PE20150161A1 (es) Uso de laquinimod de dosis alta para el tratamiento de esclerosis multiple
HRP20191121T1 (hr) Tretman multiple skleroze
BR112017004798A2 (pt) composição farmacêutica que contém um derivado de ácido hidroxâmico ou um seu sal
JP2016523260A5 (es)
BR112015030578A2 (pt) combinações farmacêuticas
CL2011000806A1 (es) Uso de etexilato de dabigatran o una sal del mismo para preparar un medicamento util para la prevencion del ictus en pacientes que padecen fibrilacion auricular.
AR090874A1 (es) Formulacion
MX2022009032A (es) Metodo de tratamiento de afecciones relacionadas con el receptor pgi2.
EA201692111A1 (ru) Фармацевтические композиции, содержащие данириксин, для лечения инфекционных заболеваний
EA201691656A2 (ru) Терапевтические способы с применением норибогаина и родственных соединений

Legal Events

Date Code Title Description
FB Suspension of granting procedure